Page 4 - Cell Shuttle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News Cellares gets $82M to make cell therapy manufacturing automated, scalable Cell therapy manufacturing is currently a manual, multi-step process that takes weeks. Startup Cellares, which is developing a system that automates the process and makes manufacturing scalable, will use the Series B financing to accelerate its work. Shares0   Talk to enough biotech industry folks and the phrase “the product is the process” is bound to come up. It refers to cell therapies, which are made by engineering human cells. In short, the medicine is an extension of the process that produced i...

Cellares Raises $82M in Series B Funding Cellares Corporation, a South San Francisco, Calif.-based life sciences technology company that automates cell therapy manufacturing, secured $82m in Series B round, bringing total funding to date to $100m. The round was led by new investor Decheng Capital with participation from existing investor Eclipse Ventures and 8VC and new backer Skyviews Life Science. The company intends to use the funds to accelerate development of the Cell Shuttle. Led by Fabian Gerlinghaus, co-founder and CEO, Cellares is advancing the Cell Shuttle, which enables end-to-...

Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ --  Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, today announced it has secured $82 million in a Series B round, bringing total funding to date to $100 million. The round was led by new investor Decheng Capital and co-led by existing investor Eclipse Ventures. Skyviews Life Science joined as a new investor, with previous investor 8VC also participating...

Cellares Adds PACT Pharma to its Early Access Partnership Program USA - English - Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount - PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center News provided by Share this article SOUTH SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ --  Cellares Corporation, a company focused on revolutionizing cell ther...